Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L02BB05
|
| gptkbp:CASNumber |
956104-40-8
|
| gptkbp:chemicalFormula |
C21H15F4N5O2
|
| gptkbp:drugClass |
antiandrogen
|
| gptkbp:genericName |
apalutamide
|
| https://www.w3.org/2000/01/rdf-schema#label |
Erleada
|
| gptkbp:indication |
non-metastatic castration-resistant prostate cancer
metastatic castration-sensitive prostate cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
androgen receptor inhibitor
|
| gptkbp:pregnancyCategory |
Not for use in women
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue hypertension weight loss rash arthralgia |
| gptkbp:synonym |
apalutamide
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:AFP-675
|
| gptkbp:bfsLayer |
7
|